ArticleBMC pharmacology & toxicology2025
Cisplatin-induced toxicity in the hippocampus: a dose-dependent mechanism of damage.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Morphological and Biochemical Changes in Rat Hippocampal Tissue Following Exposure to Different Doses of Cisplatin.Brain sciences · 2026Article
- Comparative effects of intranasal and intraperitoneal resveratrol on the eye-brain axis in a cisplatin-induced neurotoxic rat model.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCisplatin, a chemotherapeutic agent, crosses the blood‒brain barrier and induces cognitive deficits and structural brain alterations. This study aimed to assess the dose-dependent neurotoxic effects of cisplatin on rat brain and hippocampal tissues via behavioural, histopathological, and immunohistochemical evaluations.
methodsThirty-eight Wistar albino rats (60 days old) were divided into four groups: control (n = 8), cisplatin 5 mg/kg (n = 10), cisplatin 7.5 mg/kg (n = 10), and cisplatin 12 mg/kg (n = 10). The control group received saline, while the experimental groups received a single intraperitoneal dose of cisplatin. Behavioral experiments were conducted 24 h post-injection, and after three days, the rats were euthanized. Brain and hippocampal tissues were harvested for histopathology and immunohistochemistry.
resultsCompared with the control group, the cisplatin-treated groups presented significant weight loss (p < 0.001). Behavioural experiments revealed dose-dependent impairments in short- and long-term memory. Histopathological examination revealed increased neuronal necrosis/apoptosis, neuronophagia, gliosis, hyperemia, and perivascular edema, with greater severity at higher doses. These changes were most pronounced in the cisplatin 7.5 mg/kg and 12 mg/kg groups (p < 0.05), whereas the cisplatin 5 mg/kg group showed an increased severity of all symptoms except for hyperemia. Immunohistochemical staining revealed no significant changes in the Bax/Bcl-2 ratio at cisplatin 5 mg/kg, and significant increases were observed at cisplatin 7.5 mg/kg and 12 mg/kg (p < 0.05). Glial fibrillary acidic protein (GFAP) expression increased significantly in the cerebral cortex and hippocampus, especially at the highest dose.
conclusionCisplatin-induced toxicity resulted in dose-dependent increases in weight loss, neuronal necrosis/apoptosis, neuronophagia, gliosis, and perivascular edema, with significant increases in the Bax/Bcl-2 ratio and GFAP expression at cisplatin 7.5 mg/kg and 12 mg/kg, suggesting that these doses are optimal for studying neurotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.